Evommune

Evommune Interest Coverage

The Interest Coverage Ratio of Evommune (EVMN) as of Oct 29, 2026 is -24.40. In the previous year, Interest Coverage Ratio was -21.60 — a change of 12.97% (lower).

Interest Coverage

-24.40

YoY

12.97%

Last updated:

Interest Coverage Ratio of Evommune is 2025 -24.40 . Interest Coverage Ratio of Evommune was 2024 -21.60 . It decreases by 12.97% lower compared to the previous year.

The Evommune Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2023
-9.82 USD
Jan 1, 2024
-21.60 USD
Jan 1, 2025
-24.40 USD
The Evommune Interest Coverage history
YEARInterest CoverageYoY
-24.40+12.97%
-21.60+120.01%
-9.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Evommune Stock analysis

What does Evommune do? Evommune Inc generates revenue through its research and development activities focused on inflammatory diseases. The company employs a tissue-based approach using skin as a lens to develop transformative medicines in immunology and dermatology. Its primary products are advanced therapeutic solutions for inflammatory conditions, targeting pharmaceutical companies seeking to accelerate drug development. The firm serves the biotechnology and pharmaceutical sectors with its innovative R&D services. The company's business model centers on providing specialized research services to accelerate medicine development. Evommune, Inc. leverages skin tissue insights to uncover new approaches for immunology and dermatology treatments. Its services are purchased by pharmaceutical firms aiming to enhance their drug development pipelines. The firm's R&D focus on inflammatory diseases positions it as a key partner for companies in the biotech industry. Evommune Inc's revenue streams come from contractual R&D services for pharmaceutical clients. The company's tissue-based methodology for inflammatory disease research is its core offering. It develops and delivers research insights that help clients advance their medicine development in immunology and dermatology. The firm's approach targets the biotechnology sector's need for faster, more effective drug development solutions. Evommune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Evommune stock

Interest Coverage Ratio of Evommune is -24.40 in 2025.

Interest Coverage Ratio of Evommune changed from -21.60 to -24.40, representing a 12.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Evommune since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Evommune with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Evommune

All Key Metrics — Evommune